アジア太平洋の医薬品連続生産市場予測:2021-2028

◆英語タイトル:ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET FORECAST 2021-2028
◆商品コード:INK21MC015
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2021年2月8日
◆ページ数:162
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥142,500見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥171,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥228,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Inkwood社の本調査レポートは、アジア太平洋の医薬品連続生産市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、製品別分析、用途別分析、エンドユーザー別分析、地域別分析、競争状況などの情報をお届けいたします。
【レポートの概要】

KEY FINDINGSThe Asia Pacific pharmaceutical continuous manufacturing market is predicted to project a CAGR of 10.99% during the forecast period, 2021-2028. The increasing focus of prominent manufacturers with regard to the expansion of their geographic presence in the emerging countries of the region is set to provide ample growth opportunities.

MARKET INSIGHTS
Thailand, China, Vietnam, South Korea, India, Japan, Australia & New Zealand, Indonesia, and Rest of Asia Pacific, are assessed for the Asia Pacific pharmaceutical continuous manufacturing market growth evaluation. The increasing geriatric population of Japan is impacting the government healthcare expenditure. As a result, the government is adopting cost-containment measures like promoting generic drugs and biennial drug pricing revisions. Also, the big pharma companies are collaborating to form joint ventures to meet the expectant high demand for generics. In Australia & New Zealand, the rising expenditure on pharmaceutical products is estimated to drive the market growth. The recent CM (continuous manufacturing) approvals have prioritized solid dose tablet manufacturing. Simultaneously, there has been an increase in the momentum for biologics and active pharmaceutical ingredients (APIs).
In Thailand, the government’s efforts to make the country a leading destination for pharmaceuticals and medical devices and a world-class provider of medical care, is set to benefit market growth. The thriving pharmaceutical industry is attributed to the compliance with the manufacturing standards of the Pharmaceutical Inspection Cooperation Scheme (PIC/S). Owing to such factors, the country is projected to become a more attractive partner for multinational pharmaceutical manufacturers. Such developments and initiatives are expected to contribute to market growth.

COMPETITIVE INSIGHTS
Some of the major market players include, Pfizer Inc, Glatt GmbH, Gebruder Lodige Maschinenbau GmbH, Munson Machinery Company, Hosokawa Micron Corporation, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. DEVELOPMENT OPPORTUNITIES IN UNTAPPED EMERGING MARKETS
3.1.2. INCREASED ADOPTION OF PHARMACEUTICAL CONTINUOUS MANUFACTURING SYSTEMS
3.1.3. RISING GOVERNMENT INITIATIVES FOR THE ADOPTION OF CONTINUOUS MANUFACTURING SYSTEMS
3.1.4. RISE IN PRODUCTION OF LARGE MOLECULES AND BIOLOGICS
3.1.5. INCREASE IN HEALTHCARE EXPENDITURE
3.2. KEY RESTRAINTS
3.2.1. INCREASING CUSTOMER ANTICIPATIONS
3.2.2. LACK OF DEMAND FOR CONTINUOUS MANUFACTURING SYSTEMS IN UNDERDEVELOPED COUNTRIES
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. IMPACT OF COVID-19 ON PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
4.3. REGULATORY FRAMEWORK
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY INVESTMENT INSIGHTS
5. MARKET BY PRODUCT
5.1. INTEGRATED CONTINUOUS SYSTEM
5.2. SEMI-CONTINUOUS SYSTEM
5.3. CONTROL & SOFTWARE
6. MARKET BY APPLICATION
6.1. FINAL DRUG PRODUCT MANUFACTURING
6.2. API MANUFACTURING
7. MARKET BY END-USER
7.1. PHARMACEUTICAL COMPANIES
7.2. CONTRACT MANUFACTURING ORGANIZATIONS
7.3. OTHER END-USERS
8. GEOGRAPHICAL ANALYSIS
8.1. ASIA PACIFIC
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. KEY GROWTH ENABLERS
8.1.3. KEY CHALLENGES
8.1.4. KEY PLAYERS
8.1.5. COUNTRY ANALYSIS
8.1.5.1. CHINA
8.1.5.2. INDIA
8.1.5.3. JAPAN
8.1.5.4. AUSTRALIA & NEW ZEALAND
8.1.5.5. SOUTH KOREA
8.1.5.6. THAILAND
8.1.5.7. INDONESIA
8.1.5.8. VIETNAM
8.1.5.9. REST OF ASIA PACIFIC
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGER & ACQUISITIONS
9.1.2. PRODUCT LAUNCH & DEVELOPMENTS
9.1.3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
9.1.4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
9.2. COMPANY PROFILE
9.2.1. COPERION GMBH
9.2.2. ELI LILLY & COMPANY
9.2.3. GEA GROUP AG
9.2.4. GEBRUDER LODIGE MASCHINENBAU GMBH
9.2.5. GLATT GMBH
9.2.6. HOSOKAWA MICRON CORPORATION
9.2.7. KORSCH AG
9.2.8. LB BOHLE MASCHINEN + VERFAHREN GMBH
9.2.9. MUNSON MACHINERY COMPANY
9.2.10. PFIZER INC
9.2.11. SIEMENS HEALTHINEERS
9.2.12. SYNTEGON (FORMERLY BOSCH PACKAGING TECHNOLOGY)
9.2.13. THERMO FISHER SCIENTIFIC INC

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - PHARMACEUTICAL CONTINUOUS MANUFACTURING
TABLE 2: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 3: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 4: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 5: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 6: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 7: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 8: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 9: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 10: LEADING PLAYERS OPERATING IN ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET


LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: OPPORTUNITY MATRIX
FIGURE 3: VENDOR LANDSCAPE
FIGURE 4: KEY INVESTMENT INSIGHTS
FIGURE 5: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, IN 2020
FIGURE 6: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY INTEGRATED CONTINUOUS SYSTEM, 2021-2028 (IN $ MILLION)
FIGURE 7: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY SEMI-CONTINUOUS SYSTEM, 2021-2028 (IN $ MILLION)
FIGURE 8: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTROL & SOFTWARE, 2021-2028 (IN $ MILLION)
FIGURE 9: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, IN 2020
FIGURE 10: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FINAL DRUG PRODUCT MANUFACTURING, 2021-2028 (IN $ MILLION)
FIGURE 11: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY API MANUFACTURING, 2021-2028 (IN $ MILLION)
FIGURE 12: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, IN 2020
FIGURE 13: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PHARMACEUTICAL COMPANIES, 2021-2028 (IN $ MILLION)
FIGURE 14: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2021-2028 (IN $ MILLION)
FIGURE 15: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY OTHER END-USERS, 2021-2028 (IN $ MILLION)
FIGURE 16: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 17: CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
FIGURE 18: INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
FIGURE 19: JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
FIGURE 20: AUSTRALIA & NEW ZEALAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
FIGURE 21: SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
FIGURE 22: THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
FIGURE 23: INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
FIGURE 24: VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
FIGURE 25: REST OF ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アジア太平洋の医薬品連続生産市場予測:2021-2028]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆